Log in | Register

Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness

J.-C. Devaud| M. M. Berger| A. Pannatier| P. Marques-Vidal| L. Tappy| N. Rodondi| R. Chiolero| P. Voirol
Original
Volume 38, Issue 12 / December , 2012

Pages 1990 - 1998

Abstract

Purpose

Hypertriglyceridemia (hyperTG) is common among intensive care unit (ICU) patients, but knowledge about hyperTG risk factors is scarce. The present study aims to identify risk factors favoring its development in patients requiring prolonged ICU treatment.

Methods

Prospective observational study in the medicosurgical ICU of a university teaching hospital. All consecutive patients staying ≥4 days were enrolled. Potential risk factors were recorded: pathology, energy intake, amount and type of nutritional lipids, intake of propofol, glucose intake, laboratory parameters, and drugs. Triglyceride (TG) levels were assessed three times weekly. Statistics was based on two-way analysis of variance (ANOVA) and linear regression with potential risk factors.

Results

Out of 1,301 consecutive admissions, 220 patients were eligible, of whom 99 (45 %) presented hyperTG (triglycerides >2 mmol/L). HyperTG patients were younger, heavier, with more brain injury and multiple trauma. Intake of propofol (mg/kg/h) and lipids’ propofol had the highest correlation with plasma TG (r2 = 0.28 and 0.26, respectively, both p < 0.001). Infection and inflammation were associated with development of hyperTG [C-reactive protein (CRP), r2 = 0.19, p = 0.004]. No strong association could be found with nutritional lipids or other risk factors. Outcome was similar in normo- and hyperTG patients.

Conclusions

HyperTG is frequent in the ICU but is not associated with adverse outcome. Propofol and accompanying lipid emulsion are the strongest risk factors. Our results suggest that plasma TG should be monitored at least twice weekly in patients on propofol. The clinical consequences of propofol-related hyperTG should be investigated in further studies.

Keywords

References

  1. Barrientos-Vega R, Mar Sanchez-Soria M, Morales-Garcia C, Robas-Gomez A, Cuena-Boy R, Ayensa-Rincon A (1997) Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 25:33–40
    • View reference on PubMed
    • View reference on publisher's website
  2. Marik PE (2006) Dyslipidemia in the critically ill. Crit Care Clin 22:151–159 viii
    • View reference on PubMed
    • View reference on publisher's website
  3. Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A (2001) Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24:443–456
    • View reference on PubMed
    • View reference on publisher's website
  4. Maxime V, Annane D (2005) Manifestations endocriniennes liées au sepsis. Réanimation 14:230–237
    • View reference on publisher's website
  5. Bézie Y, Cattan V, Fractal LP, Lescol LP (2003) Comparaison des différentes statines: implications cliniques et choix thérapeutiques. MT Cardio 1:46–54
  6. Crook MA (2000) Lipid clearance and total parenteral nutrition: the importance of monitoring plasma lipids. Nutrition 16:774–775
    • View reference on PubMed
    • View reference on publisher's website
  7. Shams MR, Tavassoli N, Plicaud H, Genestal M (2009) Incidence and risk factors of hypertriglyceridemia in the ICU. Crit Care Med 13:130
  8. Llop J, Sabin P, Garau M, Burgos R, Perez M, Masso J, Cardona D, Sanchez Segura JM, Garriga R, Redondo S, Sagales M, Ferrer D, Pons M, Vuelta M, Fabregas X, Vitales M, Casasin T, Martinez J, Morato L, Soler M (2003) The importance of clinical factors in parenteral nutrition-associated hypertriglyceridemia. Clin Nutr 22:577–583
    • View reference on PubMed
    • View reference on publisher's website
  9. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, Paccaud F, Preisig M, Song KS, Yuan X, Danoff TM, Stirnadel HA, Waterworth D, Mooser V, Waeber G, Vollenweider P (2008) The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 8:6
    • View reference on PubMed
    • View reference on publisher's website
  10. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G (2004) Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metabol 89:219–226
    • View reference on publisher's website
  11. Vergès B (2007) Physiopathologie de la dyslipidémie du syndrome métabolique et du diabète de type 2. Nut Clin Metabol 21:9–16
    • View reference on publisher's website
  12. Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688
    • View reference on PubMed
    • View reference on publisher's website
  13. Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, ESPEN (2009) ESPEN guidelines on parenteral nutrition: intensive care. Clin Nutr 28:387–400
    • View reference on PubMed
    • View reference on publisher's website
  14. Druml W, Fischer M, Pidlich J, Lenz K (1995) Fat elimination in chronic hepatic failure: long-chain vs medium-chain triglycerides. Am J Clin Nutr 61:812–817
    • View reference on PubMed
  15. Tanaka S, Miki T, Hsieh ST, Kim JI, Yasumoto T, Taniguchi T, Ishikawa Y, Yokoyama M (2003) A case of severe hyperlipidemia caused by long-term tube feedings. J Atheroscler Thromb 10:321–324
    • View reference on PubMed
    • View reference on publisher's website
  16. Theilen HJ, Adam S, Albrecht MD, Ragaller M (2002) Propofol in a medium- and long-chain triglyceride emulsion: pharmacological characteristics and potential beneficial effects. Anesth Analg 95:923–929 (table of contents)
    • View reference on PubMed
  17. Al Riyami NB, Frohlich J (2008) Extreme hypertriglyceridemia following intravenous heparin infusion. Clin Biochem 41:907–909
    • View reference on PubMed
    • View reference on publisher's website
  18. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG (2001) Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 138:206–213
    • View reference on PubMed
    • View reference on publisher's website
  19. Que YA, Bracco D, Chioléro RL (2007) Aspects métaboliques et nutritionnels des catécholamines et des glucocortioïdesTraité de nutrition artificielle de l’adulte. Springer, Berlin, pp 183–191
  20. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41:159
    • View reference on PubMed
    • View reference on publisher's website
  21. Calandra T, Cohen J (2005) The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33:1538
    • View reference on PubMed
    • View reference on publisher's website
  22. Berger MM, Revelly JP, Wasserfallen JB, Schmid A, Bouvry S, Cayeux MC, Musset M, Maravic P, Chiolero RL (2006) Impact of a computerized information system on quality of nutritional support in the ICU. Nutrition 22:221–229
    • View reference on PubMed
    • View reference on publisher's website
  23. Soguel L, Revelly JP, Schaller MD, Longchamp C, Berger MM (2012) Energy deficit and length of hospital stay can be reduced by a two-step quality improvement of nutrition therapy: The intensive care unit dietitian can make the difference. Crit Care Med 40:412
    • View reference on PubMed
    • View reference on publisher's website
  24. Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research. Wiley, London
  25. McLeod G, Dick J, Wallis C, Patterson A, Cox C, Colvin J (1997) Propofol 2 % in critically ill patients: effect on lipids. Crit Care Med 25:1976–1981
    • View reference on PubMed
    • View reference on publisher's website
  26. Baker MT, Naguib M (2005) Propofol: the challenges of formulation. Anesthesiology 103:860–876
    • View reference on PubMed
    • View reference on publisher's website
  27. Cremer OL (2009) The propofol infusion syndrome: more puzzling evidence on a complex and poorly characterized disorder. Crit Care 13:1012
    • View reference on PubMed
    • View reference on publisher's website
  28. Devlin JW, Mallow-Corbett S, Riker RR (2010) Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Crit Care Med 38:S231
    • View reference on PubMed
    • View reference on publisher's website
  29. Vasile B, Rasulo F, Candiani A, Latronico N (2003) The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 29:1417–1425
  30. Devlin JW, Lau AK, Tanios MA (2005) Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 25:1348–1352
    • View reference on PubMed
    • View reference on publisher's website
  31. Roth MS, Martin AB, Katz JA (1997) Nutritional implications of prolonged propofol use. Am J Health Syst Pharm (AJHP) 54:694
  32. Petit V, Niot I, Poirier H, Besnard P (2007) Absorption intestinale des acides gras: faits et incertitudes. Nut Clin Metabol 21:38–45
    • View reference on publisher's website
  33. Chambrier C, Lauverjat M, Bouletreau P (2006) Emulsions lipidiques: indication des différentes émulsions lipidiques. Nut Clin Metabol 20:73–78
    • View reference on publisher's website
  34. Nordenstrom J, Carpentier YA, Askanazi J, Robin AP, Elwyn DH, Hensle TW, Kinney JM (1982) Metabolic utilization of intravenous fat emulsion during total parenteral nutrition. Ann Surg 196:221–231
    • View reference on PubMed
    • View reference on publisher's website
  35. Tappy L, Berger MM, Schwarz JM, Schneiter P, Kim S, Revelly JP, Chiolero R (2006) Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients. Clin Nutr 25:588–595
    • View reference on PubMed
    • View reference on publisher's website
  36. Chiarla C, Giovannini I, Giuliante F, Zadak Z, Vellone M, Ardito F, Clemente G, Murazio M, Nuzzo G (2010) Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care 25:361.e7–361.e12
    • View reference on publisher's website
  37. Nielsen A, Nielsen R, Riis A, Johnsen S, Sorensen H, Thomsen R (2012) The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care 16:R122
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement